1 Differential impact of antiretroviral therapy initiated before or during pregnancy on 2 placenta pathology in HIV-positive women.

3 4

5

- Nadia M IKUMI^{1†}, Thokozile R MALABA^{2†}, Komala PILLAY^{3,4}, Marta C COHEN^{5,6}, Hlengiwe P MADLALA², Mushi MATJILA⁷, Dilly ANUMBA⁸, Landon MYER², Marie-Louise NEWELL^{9,10}, and
- 6 Clive M GRAY^{1, 4*}, for the PIMS Study Group
- 7
- ¹Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University
 of Cape Town, Cape Town, South Africa
- ²Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine,
 University of Cape Town, Cape Town, South Africa
- ³Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape
 Town, South Africa
- ⁴National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa
- ¹⁵ ⁵Department of Histopathology, Sheffield Children's NHS Foundation Trust , Sheffield, UK
- ⁶Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
- 17 Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town South 18 Africa
- ⁷Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town South
 Africa
- ⁸Academic Unit of Reproductive and Developmental Medicine, University of Sheffield,
 Sheffield, United Kingdom
- ⁹School of Human Development and Health, Faculty of Medicine, University of
 Southampton, Southampton, United Kingdom
- ¹⁰School of Public Health, Faculty of Health Sciences, University of Witwatersrand,
 Johannesburg, South Africa
- 27

28 Conflict of interest statement

- 29 The authors report no conflict of interest.
- 30

31 Funding Support: The research reported in this publication was supported by the Eunice 32 Kennedy Shriver National Institute of Child Health & Human Development of the National 33 Institutes of Health under Award Number R01 HD080385 (PIMS Prematurity Immunology in 34 HIV-Infected Women and their Infants Study); also in part by the National Institute for 35 Health Research (NIHR) (17/63/26) using UK Government aid to support global health 36 research and by the Academy of Medical Sciences networking grant. The views expressed in 37 this publication are those of the author(s) and not necessarily those of the NICH NIH, NIHR 38 or the UK Department of Health and Social Care.

- 39
- 40 [†]Co-First Authors
- 41

42 *Corresponding Author

Clive M Gray, Division of Immunology, Institute of Infectious Disease and Molecular
Medicine, Falmouth Building, Faculty of Health Sciences, University of Cape Town, Anzio
Road, Observatory, Cape Town, South Africa, 7925; Tel: +27 21406 6616; Email:
<u>clive.gray@uct.ac.za</u>

47

48 Short Title

49 ART and placenta pathology

- 50
- 51 Word count: Body: 3220; Abstract: 239
- 52

53 ABSTRACT

54 **Objective:**

55 To examine the association between timing of ART initiation in HIV-infected women and 56 placental histopathology.

57

58 **Design:**

59 A nested sub-study in a larger cohort of HIV-infected women which examined the 60 association between ART status and birth outcomes.

61

62 Methods:

Placentas (n=130) were examined for histopathology from two ART groups: *stable* (n=53), who initiated ART before conception and *initiating* (n=77), who started ART during pregnancy (median [IQR] 15 weeks gestation [11-18]). Using binomial regression we quantified associations between ART initiation timing with placental histopathology and pregnancy outcomes.

68

69 **Results:**

One-third of all placentas were <10th percentile weight-for-gestation and there was no 70 71 significant difference between ART groups. Placental diameter, thickness, cord insertion 72 position and fetal-placental weight ratio were also similar by group. However, placentas from the stable group showed increased maternal vascular malperfusion (MVM) (39.6% vs 73 74 19.4%), and decreased weight (392g vs 422g, p=0.09). MVM risk was twice as high (RR 2.03 75 [95% CI: 1.16 - 3.57]; p=0.01) in the stable group; the increased risk remaining significant 76 when adjusting for maternal age (RR 2.04 [95% CI: 1.12 - 3.72]; p=0.02). Furthermore, MVM 77 was significantly associated with pre-term delivery (PTD) and low birth weight (LBW) 78 (p=0.002 and p<0.0001, respectively).

79

80 **Conclusion:**

81 Preconception initiation of ART was associated with an increased MVM risk, and may 82 contribute to placental dysfunction. The association between MVM with PTD and LBW 83 suggests that a placenta-mediated mechanism likely links the putative association between 84 long-term use of ART and adverse birth outcomes.

85

Keywords: HIV, placenta pathology, timing of ART initiation, pre-term delivery, small forgestational age

88

90 Introduction

91 Antiretroviral treatment (ART) during pregnancy is not only of benefit for both the mother and infant, substantially decreasing MTCT, but is also proven to be most effective in 92 reducing maternal and child mortality.^[1,2] Like many other countries, South Africa has now 93 94 fully adopted universal ART for life for all HIV-positive women upon diagnosis, including pregnant women.^[3] However, the extensive rollout and uptake of ART from before or early 95 pregnancy has led to a rapid rise in fetal exposure to ART; where such in-utero drug 96 exposure has been associated with increased risk of adverse birth outcomes: including 97 preterm delivery (PTD)^[4–6], low birth weight (LBW)^[7] and small-for-gestational age (SGA) 98 infants^[4,8]. 99

100

101 HIV infection in pregnancy, even in the absence of ART, has been associated with an 102 increased risk of adverse birth outcomes which is thought to be through inflammationmediated disruption of placental development and function^[9,10]. How maternal HIV 103 infection impacts placental structure and function is thus important to consider as it can 104 affect both maternal health, as seen in eclampsia^[11], and fetal health, as seen with PTD and 105 SGA^[9,12-14]. Uncharacteristic placental shapes and sizes may indicate decreased placental 106 efficiency, and maternal supply-line deprivation^[15,16]. Histologic chorioamnionitis reflects 107 maternal and fetal inflammatory responses to ascending infection^[17,18], and is a major cause 108 of spontaneous PTD^[19-21]. Despite recognition of the importance of the placenta in adverse 109 birth outcomes, there is scant data on the impact of *in-utero* ART exposure on placental 110 111 development and pathology, and subsequent adverse birth outcomes.

112

Within a large cohort of HIV-positive women, we set out to systematically examine the histopathology of placentas collected at delivery from HIV-positive women initiating ART before or during pregnancy, to inform understanding of the impact of ART initiation timing on placental pathology. We conjectured that initiation of ART during pregnancy would result in greater inflammation-linked placental pathology than ART initiated before pregnancy.

118

119 Methods

We performed a nested sub-study in the Prematurity Immunology in HIV-infected Mothers 120 and their infants Study (PIMS) cohort in Cape Town, South Africa^[22]. PIMS was a prospective 121 cohort study investigating the association between ART use and adverse birth outcomes, in 122 particular PTD, SGA and LBW^[22]. HIV-positive pregnant women aged ≥18 years seeking 123 124 antenatal care (ANC) services at the Gugulethu Midwife Obstetric Unit (MOU) were recruited between April 2015 and October 2016, at ≤24 weeks gestation. Whole placentas 125 were collected at delivery and only those graded as good quality (grades 1-3)^[23] were 126 127 processed within 24 hours. Included were women who initiated ART before pregnancy 128 (stable group), or during pregnancy (initiating group). ART regimens consisted 129 predominately of tenofovir (TDF) + lamivudine (3TC)/emtricitabine (FTC) + efavirenz (EFV)^[22]. 130

131

132 Ethical considerations

133 The PIMS study protocol, informed consent forms and all data collection tools were 134 approved by the University of Cape Town's, Faculty of Health Sciences Human Research 135 Ethics Committee (UCT FHS-HREC) (HREC 739/2014) and the University of Southampton

136 Faculty of Medicine Ethics Committee on (12542 PIMS). Written informed consent was

137 obtained from all study participants, including placenta collection for the nested cohort.

138

139 Data collection

At first ANC visit, gestational age (GA) was determined by ultrasound scan (USS) by a research sonographer using a standardized assessment protocol. Obstetric outcomes, including date of delivery and birthweight, were obtained from clinical records. Maternal CD4 and viral load measurements were obtained from hospital records at the time closest to the first ANC visit. Body Mass Index (BMI) was calculated from weight and height measurements; blood pressure were measured at the first ANC visit (baseline) and during follow-up.

147

148 Placenta collection and processing

149 Whole placentas were collected at delivery and fixed in 10% buffered formalin. Placental 150 histopathological examination were performed in the Department of Pathology, Red Cross 151 Memorial Children's Hospital, Cape Town, South Africa. Specimens were examined from the 152 umbilical cord, membranes and placental disk and scored following the Amsterdam Placental Workshop Group Consensus Statement^[24]. Briefly, four blocks were prepared from 153 each placenta, one block included a roll of the extraplacental membranes and two cross 154 155 sections of the umbilical cord, one from the placental insertion, and one close to the fetal 156 end. In addition, three blocks each contained a full-thickness section of the placenta 157 parenchyma, one from a visibly abnormal area if present and two sections from 158 macroscopically normal tissue including one from the cord insertion. The tissue sections 159 were $3-5\mu m$ thick and were cut and stained with hematoxylin and eosin for histological 160 examination. Macroscopic and microscopic features were combined to report placenta 161 pathology. For the sake of pathology scoring rigour, sections were also assesed in the 162 Department of Histopathology, Sheffield Children Hospital NHS Foundation Trust, Sheffield, 163 UK.

164

165 Variables of interest

166 Placenta pathology was based on placenta weight-for-gestational age, fetal-placental weight 167 ratio and features of placenta pathology. All placenta weights were reported as trimmed 168 weights, after removal of umbilical cords and membranes. Placenta weight percentiles by gestational age and fetal-placenta ratios were categorized as small (<10th), appropriate (10-169 90th) and large (>90th) for gestational age.^[25] Microscopically, the placenta was examined for 170 171 features of meconium exposure, based on the presence and amount of meconium-laden 172 macrophages in the placental membranes, with some cases showing features of prolonged exposure characterized by meconium deep in the chorionic plate and umbilical cord; 173 amnion degeneration and chorion vascular muscle necrosis^[26]. Histologic chorioamnionitis 174 was defined as the presence of acute inflammation in the placenta, with or without a fetal 175 inflammatory response^[27,28]. Maternal vascular malperfusion (MVM) was defined as a 176 177 constellation of macroscopic and histologic features representing a pattern of injury in the 178 placenta as a result of maternal vascular abnormalities. The presence of decidual 179 vasculopathy was indicative of maternal vascular malperfusion. In the absence of decidual 180 vasculopathy, MVM was indicated by a small placenta for gestational age accompanied by 181 at least two villous changes (villous infarct, retroplacental haematoma, accelerated villous 182 maturation or distal villous hypoplasia). In the case of normal placenta weights for 183 gestational age, at least 3-4 villous features were noted to be placed in the category of MVM.^[24,29,30] Decidual arteriopathy was defined as abnormal or incomplete remodelling of 184 decidual spiral arterioles resulting in fibrinoid necrotic lesions^[24,29,30]. Chronic deciduitis was 185 defined as abnormal infiltration of lymphocytes and plasma cells in the decidua^[24,31]. 186 187 Placenta disk dimensions were recorded as maximum linear dimension (length), greatest 188 dimension of the axis perpendicular to the *length* (width) and the thickness. Cord insertion 189 referred to site of insertion on the placenta in relation to the margin of the placenta 190 classified as central, off-centre and marginal based on the distance from the margin.

191

Secondary outcomes included PTD, SGA and LBW. PTD was defined as delivery at <37 weeks' GA^[32]. Birthweight was categorized as low (LBW, <2500g), normal (NBW, 2500-4000g) and high (HBW, >4000g)^[33]. Size for gestational age, based on gender-specific INTERGROWTH-21st project standards, was defined as small for gestational age (SGA) for infants with birthweight <10th percentile for gestational age, appropriate for gestational age (AGA) for those between 10-90th percentile and large for gestational age (LGA) for those >90th percentiles^[34].

199

200 Statistical analysis

201 Statistical analyses were performed using STATA version 12.0 (Stata Corporation, College 202 Station, Texas, USA) and R. Analyses focused on placenta pathology outcomes by ART 203 initiation before or during pregnancy. The impact of ART timing on features of placental 204 pathology was summarized using an Alluvial plot generated using the *ggalluvial* package in R^[35]. Secondary analyses focused on birth outcomes (PTD, LBW and SGA) related to features 205 206 of placenta pathology. In bivariable analyses, proportions were compared using chi-207 squared/Fishers exact test and rank-sum tests. Associations between baseline 208 characteristics and placenta pathology outcomes (small placental weight for GA, MVM and 209 chorioamnionitis) were assessed using binomial regression. Results were presented as risk 210 ratios (RR) with 95% confidence intervals (CI) generated using the forestplot package in R (R package version 1.9)^[36]. For secondary analyses of birth outcomes, given the limited sample 211 size, only bivariate associations were assessed. As placenta weight and MVM abnormalities 212 213 were likely to originate in early gestation, we explored associations between timing of ART 214 initiation and the placenta pathologies. For MVM, as advanced maternal age has been shown to increase the risk of placental dysfunction, ^[37] we applied a multivariable regression 215 216 model to adjust for maternal age differences recorded at booking between ART groups. To 217 assess potential risk factors for PTD, SGA and LBW we compared differences between groups using the chi² test or Fisher's exact test. Missing values were excluded from these 218 219 analyses.

- 220
- 221
- 222
- 223 224

225 Results

- from the initiating group of women. Maternal and obstetric characteristics are summarised in Table 1.
- 229

230 Maternal characteristics

231 Women in the stable group were older (median 33 years, IQR 28-37) than initiating women 232 (median 28, IQR 25-32). Median GA at first ANC visit was 15 weeks (IQR 11-18), with no 233 differences by ART initiation timing group (Table 1). Overall, 119 (91.5%), women were on a 234 fixed dose regimen of Tenofovir (TDF) + Lamivudine (3TC) + Efavirenz (EFV), 2 (1.5%) were 235 on Zidovudine (AZT) + Lamividune (3TC) + Nevirapine (NVP), 6 (4.6%) were on AZT + 236 Emtricitabine or Lamivudine (XTC) + EFV with no difference between the groups; only 3 237 (2.3%; all in the stable group) were on a protease inhibitor (PI)-based regimen. Stable 238 women had significantly higher median CD4 T cell counts at enrolment (455 cells/ml, IQR 239 381 - 602) than initiating women (369.5 cells/ml, IQR 251 - 534.5). Most women (78.4%) 240 were overweight or obese, not significantly different by ART group. Initiating women were 241 more likely to be pre-hypertensive than stable women (28.6% vs 11.3%). Alcohol was the 242 most used substance, with 22% of women reporting alcohol use < 30 days prior to first ANC 243 visit (Supp. Table 1). There was no difference in smoking or recreational drug use between 244 the two groups.

245

246 Infant characteristics

247 Of the 130 live singleton births, 58 (44.6%) were female and 72 (55.3%) male (Table 2), with 248 no sex difference by ART timing group. Overall, median gestation at delivery was 39 weeks 249 (IQR 38 - 40), and PTD incidence was low (6.9%) with no difference by timing of ART 250 initiation. While median birthweight was also similar between ART groups, there was a 251 tendency towards differences in the percentage of LBW (11.3% vs 6.5%) and HBW (1.9% vs 252 9.1%) deliveries in the stable and initiating group respectively; but not reaching statistical 253 significance. The tendency towards increased >4000g macrosomia births in the ART 254 initiation during pregnancy group was not associated with birth complications. Differences 255 were also observed in size for gestational age, where 12 (9.2%) infants were SGA overall, 256 with 8 (15.1%) in the stable and 4 (5.2%) in the initiating group.

257

258 Placental Pathology.

259 Table 3 shows placenta characteristics and pathology stratified by timing of ART initiation, 260 and Figures 1A-D show representative images of some of the features of placenta pathology 261 included in our analysis: chorioamnionitis (Figure 1A), neutrophilic infiltrate involving the 262 cord vein representing a fetal response (Figure 1B) and decidual artery atherosis (Figure 1C). Median placenta weight was 412g (IQR 350 - 480) overall, 393g in the stable and 422g in the 263 initiating group (p=0.09). Overall, 43 (33%) placentas were <10th percentile weight-for-264 265 gestation, with no significant differences between ART groups; placental diameter, thickness 266 or cord insertion were also similar in each group as was the Fetal-Placental weight ratio. 267 Meconium exposure was identified in 22 (19.2%) cases, similar in both ART groups. 268 Chorioamnionitis was present in 19 (14.6%) cases, with a higher percentage in initiating 269 than in stable women, but not reaching statistical significance. MVM was significantly higher in placentas from stable than initiating women (39.2% vs 19.5%; p=0.01). There were no cases of chronic basal villitis, chronic chorioamnionitis, eosinophilic/T-cell vasculitis or chronic histiocytic intervillositis. Chronic decidual perivasculitis was included in cases of chronic deciduitis.

274

To discount selection bias due to collection of placentas from a sub-group of women, we compared maternal characteristics in "no-placenta" versus "placenta" collection for each ART group (Supp Table 2) in the larger PIMS cohort. Importantly, blood pressure was no different in the wider cohort (n=421), irrespective of ART group, indicating that the observed MVM in the smaller placenta stable group was not due to any bias in a pre- or hypertensive state, which could have impacted on our observations.

281

282 Figures 2A-C shows the relative risk of placenta pathology by ART group and maternal 283 characteristics. In unadjusted models, women who were overweight (RR 0.46 [95% CI: 0.27-284 081]; p=0.007) and obese (RR 0.37 [95% CI: 0.21 - 0.64]; p<0.0001) were less likely to have 285 small-for-gestational age placentas (Figure 2A). None of the variables explored were 286 associated with significant risk of chorioamionitis (Figure 2B). The risk of MVM (Figure 2C) 287 was twice as high (RR 2.03 [95% CI: 1.16 - 3.57]; p=0.01) in stable than in initiating women 288 and remained significant when adjusting for maternal age (RR 2.04 [95% CI: 1.12 - 3.72]; 289 p=0.02). The impact of ART timing on placental pathology is summarized in the Alluvial plot 290 in Figure 2D, emphasizing the occurrence of MVM in women initiating ART pre-conception. 291 The association between placenta pathology and PTD, SGA and LBW (Table 4) was 292 significant for MVM (PTD: p=0.002; LBW: p<0.0001), and borderline for SGA (p=0.09). In 293 addition, SGA deliveries were more likely to present with meconium exposure, indicating 294 fetal distress (p=0.01).

295

296 Discussion

297 We examined the association between timing of ART initiation in HIV-positive women and 298 placental pathology, and with subsequent birth outcomes. Placentas from women who had 299 initiated ART pre-conception, but not those initiating during pregnancy, showed significantly 300 increased maternal vascular malperfusion (MVM). There was no evidence for overt 301 maternal or fetal inflammation in either ART group, contrary to our initial supposition. As 302 MVM was significantly associated with PTD and LBW, our findings suggest that associations 303 between ART and adverse birth outcomes may be placenta-mediated, especially so for 304 women initiating ART before pregnancy, where there is antiretroviral drug exposure during 305 placental implantation and development.

306

Previous studies of HIV-positive women initiating ART before or during pregnancy have focused on quantifying risk of PTD^[1,4,7,38–41], SGA^[4,7,41,42], LBW^[7,38,39], stillbirth^[43] and/or neonatal death^[42]; virologic failure^[44]; MTCT^[45] maternal plasma angiogenic factors^[46], and maternal virologic and immunologic responses^[47]. This is the first study to investigate placenta pathology in association with timing of ART initiation. In our study, women who initiated ART before pregnancy were significantly older, which could have accounted for the observed MVM. However, when we controlled for maternal age, MVM remained 314 significantly associated with pre-conception ART initiation. Thus, ART initiation pre-315 conception is a substantial risk factor for MVM.

316

317 MVM represents a pattern of placental injury which affects the maternal vasculature and 318 circulation and often associates with significantly increased risk of adverse effects to the fetus^[24,29]. We found that the high incidence of MVM in our study was consistent with 319 findings from a previous HIV-positive pregnancy cohort^[48], albeit MVM in our study 320 321 associated with PTD and LBW. We posit that prolonged ART, initiated pre-conception, is 322 likely resulting in perturbed placental development and poor perfusion and function giving 323 rise to adverse birth outcomes. Interestingly, there was a non-significantly higher proportion 324 of macrosomia births in the women initiating ART during pregnancy, perhaps reflecting the 325 higher proportions of mothers with a high BMI in this group. Although macrosmia has been associated with shoulder dystocia, neonatal and maternal trauma, ^[49] hypogycaemia, ^[50] this 326 327 was not observed in our larger PIMS cohort when we stratified the groups by time of ART initiation (before versus during pregnancy).^[51] 328

329

330 Although HIV-positive individuals on ART have been shown to have a high prevalence of hypertension^[52], women initiating ART prior to pregnancy in our study were less likely to be 331 332 pre- or hypertensive than those initiating during pregnancy. Additionally, we did not find 333 any associations between MVM and hypertensive disorders in our cohort, although 334 hypertensive disorders of pregnancy, including preeclampsia and chronic hypertension, are the classical maternal clinical features associated with an increased risk of MVM^[53-55]. Our 335 336 data suggests that placental research should form an integral part when exploring 337 interventions aimed at mitigating adverse birth outcome associated with ART use in 338 pregnancy.

339

340 The impact of ART exposure on the placenta is under-explored and we speculate that exposure of ART before or during early pregnancy results in systemic maternal inflammation 341 that may disrupt vasculogenesis and angiogenesis^[9]. In our cohort, the underlying 342 343 mechanism leading to this disruption may be dysregulation of pro-angiogenic mediators 344 including placental growth factor (PIGF), soluble endoglin (sEng) and angiopoietin-1 (Ang-1). 345 Although data is scarce, previous findings demonstrate that maternal HIV infection and ART 346 exposure is associated with an altered pro-angiogenic state; including lower PIGF, higher sEng, decreased Ang-2 and increased Ang-1^[10,56–58]. Based on previous evidence linking ART 347 348 with dysregulated angiogenesis and compromised placental vascular development in early 349 pregnancy, we postulate that the higher incidence of MVM in women who initiate ART 350 before pregnancy was likely due to ART-associated shifts towards an anti-angiogenic state ^[59]. This may account for the increased MVM in women intiating ART pre-conception; 351 352 suggestive that ART exposure could have detrimental effects on placental development 353 characterized by altered uterine and intervillous blood flow dynamics.

354

Of potential importance for the interpretation of our findings was that over three quarters of the women were either overweight or obese at first antenatal visit; increased BMI at that time was associated with a decreased likelihood of a small placenta at delivery. We did not have reliable assessments of BMI pre-pregnancy, but in other studies^[53,54] elevated pre359 pregnancy BMI has been associated with large for gestational age placentas and altered 360 placental metabolic function. We recently showed from our larger PIMS cohort, maternal 361 obesity can increase the risk of having high birthweight and large for gestational age infants 362 and that incremental gestational weight gain increased the risk of having a spontaneous preterm delivery.^[55] Beyond the effect of high BMI during pregnancy on the placenta, it is 363 also associated with childhood obesity and cardiovascular diseases in later life.^[56,57] 364 365 Although our study was limited in this regard, interventions targeting the risks associated 366 with the high rate of obesity among women of child-bearing age or during gestation should 367 not be ignored

368

369 The main strength of our study is the cohort design allowing us to compare two groups of 370 pregnant women receiving the same NNRTI-based ART regimen and enrolled early in 371 gestation, with data collected and samples investigated according to a strict protocol. 372 Additional strength lies in the ultrasound-based gestational age assessment, leading to 373 accurate PTD determination. Limitations include the non-random nature of the selection of 374 the nested cohort, giving rise to potential differences in maternal characteristics between 375 ART groups or placentas collected. However, we doubt this would affect our findings as: a) 376 there was no significant difference in maternal characteristics when we compared the 377 placenta sub-group with the overall cohort and b) the rates of stillbirths and miscarriages 378 were less than 5% in the larger PIMS cohort, with no differences in pregnancy loss when 379 groups were stratified by time of ART initiation. All staff in the three clinics where women 380 delivered were trained in placenta collection (with no exclusion criteria), and placentas were 381 transported to the laboratory for processing immediately.

382

In conclusion, we show women receiving ART pre-conception were at increased risk of MVM, suggestive of placental dysfunction. In turn, the association between MVM with PTD and LBW suggests that a placenta-mediated mechanism links the putative association between ART and adverse birth outcomes. Our results further intimate that monitoring placental function in women who initiated ART prior to conception is warranted and that adjunctive therapies that target placental insufficiency in these women can alleviate the burden of adverse birth outcomes.

ACKNOWLEDGEMENTS

- 392 We thank all the study participants in this study; and all the members of the PIMS study. We 393 also wish to thank Sue Ford, Colin Newel for data management and Michael Zulu for 394 specimen processing.
- 395

396 Author contributions

- 397 Clive M Gray, Marie-Louise Newell, Thokozile R Malaba, Landon Myer: Conceptualization
- 398 and design of the study
- 399 Thokozile R Malaba, Hlengiwe P Madlala: study conduct, data collection and specimen 400 collection
- 401 Nadia M Ikumi: Laboratory and sample preparation
- 402 Komala Pillay, Marta Cohen: Histopathology scoring and interpretation
- 403 Nadia M Ikumi, Thokozile R Malaba: Statistical analysis
- 404 Nadia M Ikumi, Thokozile R Malaba, Clive Gray, Hlengiwe P Madlala, Marie-Louise Newell,
- 405 Mushi Matjila, Dilly Anumba, Landon Myer: Writing the manuscript, review and editing
- 406

408 **REFERENCES**

409 Aniji CD, Towobola OA, Hoque ME, Mashamba TJ, Monokoane S. Impact of 1. 410 antiretroviral therapy on pregnancy outcomes. South Afr J HIV Med [Internet]. 2013 411 Nov 22;14(4):176. Available from: 412 http://www.sajhivmed.org.za/index.php/sajhivmed/article/view/834 413 2. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and Risks 414 of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med [Internet]. 415 2016;375(18):1726-37. Available from: 416 http://www.ncbi.nlm.nih.gov/pubmed/27806243 417 3. World Health Organization. Programmatic Update Use of Antiretroviral Drugs for 418 Treating Pregnant Women and Preventing HIV Infection in Infants Executive 419 Summary. Vol. 45, World Health Organization. Geneva; 2012. 420 4. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active 421 antiretroviral therapy and adverse birth outcomes among HIV-infected women in 422 Botswana. J Infect Dis [Internet]. 2012 Dec 1;206(11):1695–705. Available from: 423 http://www.ncbi.nlm.nih.gov/pubmed/23066160 424 5. Short C-ES, Douglas M, Smith JH, Taylor GP. Preterm delivery risk in women initiating 425 antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med 426 [Internet]. 2014 Apr;15(4):233–8. Available from: 427 http://www.ncbi.nlm.nih.gov/pubmed/24025074 428 6. Thorne C, Patel D, Newell M-L. Increased risk of adverse pregnancy outcomes in HIV-429 infected women treated with highly active antiretroviral therapy in Europe. AIDS 430 [Internet]. 2004 Nov:18(17):2337–9. Available from: 431 http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002 432 030-200411190-00019 433 Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, et al. Antiretroviral 7. 434 Therapy in Relation to Birth Outcomes among HIV-infected Women: A Cohort Study, J 435 Infect Dis [Internet]. 2016 Apr 1;213(7):1057–64. Available from: 436 http://www.ncbi.nlm.nih.gov/pubmed/26265780 437 8. Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S, et al. Reassuring 438 Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of 439 Mother-to-Child Transmission of HIV in Botswana. J Acquir Immune Defic Syndr 440 [Internet]. 2016 Apr 1;71(4):428–36. Available from: 441 http://www.ncbi.nlm.nih.gov/pubmed/26379069 442 9. Weckman AM, Ngai M, Wright J, McDonald CR, Kain KC. The Impact of Infection in 443 Pregnancy on Placental Vascular Development and Adverse Birth Outcomes. Front 444 Microbiol [Internet]. 2019 Aug 22;10. Available from: 445 https://www.frontiersin.org/article/10.3389/fmicb.2019.01924/full 446 10. Conroy AL, McDonald CR, Gamble JL, Olwoch P, Natureeba P, Cohan D, et al. Altered 447 angiogenesis as a common mechanism underlying preterm birth, small for gestational 448 age, and stillbirth in women living with HIV. Am J Obstet Gynecol [Internet]. 2017 449 Dec;217(6):684.e1-684.e17. Available from: 450 https://linkinghub.elsevier.com/retrieve/pii/S0002937817311857 451 11. Fisher SJ. Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol 452 [Internet]. 2015 Oct;213(4):S115–22. Available from: 453 https://linkinghub.elsevier.com/retrieve/pii/S0002937815009126 454 12. Romero R, Kusanovic JP, Chaiworapongsa T, Hassan SS. Placental bed disorders in 455 preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. Best 456 Pract Res Clin Obstet Gynaecol [Internet]. 2011 Jun;25(3):313–27. Available from: 457 http://www.ncbi.nlm.nih.gov/pubmed/21388889 458 13. Doyle RM, Alber DG, Jones HE, Harris K, Fitzgerald F, Peebles D, et al. Term and 459 preterm labour are associated with distinct microbial community structures in

460		placental membranes which are independent of mode of delivery. Placenta
461		[Internet]. 2014 Dec;35(12):1099–101. Available from:
462		https://linkinghub.elsevier.com/retrieve/pii/S0143400414008194
463	14.	Morgan T. Role of the Placenta in Preterm Birth: A Review. Am J Perinatol [Internet].
464		2016 Jan 5;33(03):258–66. Available from: http://www.thieme-
465		connect.de/DOI/DOI?10.1055/s-0035-1570379
466	15.	Salafia CM, Yampolsky M, Misra DP, Shlakhter O, Haas D, Eucker B, et al. Placental
467		surface shape, function, and effects of maternal and fetal vascular pathology.
468		Placenta [Internet], 2010 Nov:31(11):958–62, Available from:
469		https://linkinghub.elsevier.com/retrieve/pii/S0143400410003395
470	16.	Freedman AA. Hogue CJ. Marsit CJ. Rajakumar A. Smith AK. Goldenberg RL. et al.
471		Associations Between the Features of Gross Placental Morphology and Birthweight.
472		Pediatr Dev Pathol [Internet], 2019 May 16:22(3):194–204, Available from:
473		http://iournals.sagepub.com/doi/10.1177/1093526618789310
474	17	Redline RW Inflammatory response in acute chorioamnionitis Semin Fetal Neonatal
475	±/.	Med [Internet] 2012 Feb:17(1):20–5 Available from:
476		https://lipkinghub.elsevier.com/retrieve/pii/S174/165X11000916
477	18	Ategeka I Wasswa R Olwoch P Kakuru A Natureeha P Muehlenhachs A et al The
478	10.	nrevalence of histologic acute chorioamnionitis among HIV infected pregnant women
470 //79		in Liganda and its association with adverse hirth outcomes. Robboy SL editor, PLoS
480		Ω no [Internet] 2019 Apr 11:14(A):00215058 Available from:
480		http://dx plos org/10.1371/journal pape 0215058. Available from:
401	10	Galinshy R. Balglass GR. Hooper SR. Black MJ. Moss TIM. The Consequences of
402	19.	Charles and the second se
403		2012:2012:1-11 Available from: http://www.bindowi.com/journals/in/2012/412821/
404	20	Dringe AL Ma L Kappan DS Alvarez M Gisslen T Harris DA et al. The placental
405	20.	Prince AL, Ma J, Kallian PS, Alvarez M, Gissien T, Harris KA, et al. The procental
480		with and without charics main itic. Am L Obstat Curses L Internet 2010
487		May 214/E) C27 of C27 of C27 of C Available frame.
488		V(ay) (1) (5) (527.61-627.616. Available from:
489	24	Mustham INA Hansen NL Cohners Chillele F. Man Manuel K. Sénahas DL at al
490	21.	Wortham JW, Hansen NI, Schrag SJ, Hale E, Van Meurs K, Sanchez PJ, et al.
491		Chorioamnionitis and Culture-Confirmed, Early-Onset Neonatal Infections. Pediatrics
492		[Internet]. 2016 Jan;137(1):e20152323. Available from:
493	22	http://pediatrics.aappublications.org/lookup/doi/10.1542/peds.2015-2323
494	22.	Malaba TR, Gray CM, Myer L, Newell M-L. Cohort Profile: Prematurity Immunology in
495		HIV-infected Mothers and their infants Study (PIMS). medRixv [Internet].
496		2020;2020.03.18.20033654. Available from:
497		http://medrxiv.org/content/early/2020/03/23/2020.03.18.20033654.abstract
498	23.	Malaba TR, Gray CM, Myer L, Newell M-L. Cohort Profile: Prematurity Immunology in
499		HIV-infected Mothers and their infants Study (PIMS). medRxiv [Internet]. 2020 Jan
500		1;2020.03.18.20033654. Available from:
501		http://medrxiv.org/content/early/2020/03/23/2020.03.18.20033654.abstract
502	24.	Khong TY, Mooney EE, Ariel I, Balmus NCM, Boyd TK, Brundler M-A, et al. Sampling
503		and Definitions of Placental Lesions: Amsterdam Placental Workshop Group
504		Consensus Statement. Arch Pathol Lab Med [Internet]. 2016 Jul;140(7):698–713.
505		Available from: http://www.archivesofpathology.org/doi/10.5858/arpa.2015-0225-
506		CC
507	25.	Kraus FT. Placenta Pathology. American Registry of Pathology, editor. American
508		Registry of Pathology; 2004.
509	26.	Kim B, Oh S, Kim J-S. Placental Lesions in Meconium Aspiration Syndrome. J Pathol
510		Transl Med [Internet]. 2017 Sep 15;51(5):488–98. Available from:
511		http://jpatholtm.org/journal/view.php?doi=10.4132/jptm.2017.07.20

512	27.	Kallapur S, Presicce P, Rueda C, Jobe A, Chougnet C. Fetal Immune Response to
513		Chorioamnionitis. Semin Reprod Med [Internet]. 2014 Jan 3;32(01):056–67. Available
514		from: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0033-1361823
515	28.	Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute
516		chorioamnionitis and funisitis: definition, pathologic features, and clinical
517		significance. Am J Obstet Gynecol [Internet]. 2015 Oct:213(4):S29–52. Available from:
518		https://linkinghub.elsevier.com/retrieve/nii/S0002937815009102
519	29	Ernst I.M. Maternal vascular malnerfusion of the placental hed. APMIS [Internet]
520	23.	$2018 \text{ [ul:} 126/7) \cdot 551 = 60$ Available from: http://doi.wilov.com/10.1111/apm.12833
520	20	Loider A. Fatal Vascular Malnarfusian, Arab Dathal Lab Mad [Internat], 2017
521	50.	New 141/11/1484 O Avoilable from:
522		100,141(11):1484-9. Available from:
523	24	nttp://www.archivesofpathology.org/doi/10.5858/arpa.2017-0212-KA
524	31.	Ziadie M. Chronic deciduitis [Internet]. PathologyOutlines.com website. [cited 2020
525		Mar 30]. Available from:
526		https://www.pathologyoutlines.com/topic/placentachronicdecid.html
527	32.	World Health Organization. Preterm Birth [Internet]. [cited 2019 Mar 30]. Available
528		from: https://www.who.int/news-room/fact-sheets/detail/preterm-birth
529	33.	Ota E, Haruna M, Suzuki M, Anh DD, Tho LH, Tam NTT, et al. Maternal body mass
530		index and gestational weight gain and their association with perinatal outcomes in
531		Viet Nam. Bull World Health Organ [Internet]. 2011 Feb 1;89(2):127–36. Available
532		from: http://www.who.int/bulletin/volumes/89/2/10-077982.pdf
533	34.	Papageorghiou AT, Kennedy SH, Salomon LJ, Altman DG, Ohuma EO, Stones W, et al.
534		The INTERGROWTH-21 st fetal growth standards; toward the global integration of
535		pregnancy and pediatric care. Am J Obstet Gynecol [Internet], 2018 Feb: 218(2):S630-
536		40 Available from: https://linkinghub elsevier.com/retrieve/nii/S0002937818300127
537	35	Brunson IC ggalluvial Alluvial Plots in "ggnlot?" [Internet] 2020 Available from:
538	55.	https://cran.r-project.org/package=ggalluvial
530	26	Gordon M. Lumlov T. forestalet: Advanced Forest Plot Using "grid" Graphics 2019
540	27	Loop SC Hoozoll AED Dilworth MP Mills TA Jones PL Decented Dysfunction
540	57.	Lean SC, Reazen AEP, Diworth WR, Whis TA, Jones RL. Placental Dystunction
541		Matamal And Manage Cai Day [lutamat] 2017;7(1):0077. Available frame
542		Maternal Age women. Sci Rep [Internet]. 2017;7(1):9677. Available from:
545	20	nttp://www.ncbi.nim.nin.gov/pubmed/28852057
544	38.	Machado ES, Hofer CB, Costa IT, Nogueira SA, Oliveira RH, Abreu TF, et al. Pregnancy
545		outcome in women infected with HIV-1 receiving combination antiretroviral therapy
546		before versus after conception. Sex Transm Infect [Internet]. 2009 Apr;85(2):82–7.
547		Available from: http://www.ncbi.nlm.nih.gov/pubmed/18987014
548	39.	Chetty T, Thorne C, Coutsoudis A. Preterm delivery and small-for-gestation outcomes
549		in HIV-infected pregnant women on antiretroviral therapy in rural South Africa:
550		Results from a cohort study, 2010-2015. PLoS One [Internet]. 2018;13(2):e0192805.
551		Available from: http://www.ncbi.nlm.nih.gov/pubmed/29470508
552	40.	Stoner MCD, Cole SR, Price J, Winston J, Stringer JSA. Timing of Initiation of
553		Antiretroviral Therapy and Risk of Preterm Birth in Studies of HIV-infected Pregnant
554		Women: The Role of Selection Bias. Epidemiology [Internet]. 2018;29(2):224–9.
555		Available from: http://www.ncbi.nlm.nih.gov/pubmed/29045283
556	41.	Malaba TR. Phillips T. Le Roux S. Brittain K. Zerbe A. Petro G. et al. Antiretroviral
557		therapy use during pregnancy and adverse birth outcomes in South African women.
558		Int Enidemio [Internet] 2017 Oct 1:46(5):1678–89 Available from:
559		https://academic.oup.com/ije/article/46/5/1678/4055952
560	42	Santosa WB Staines-Urias E Tshivuila-Matala COO Norris SA Hemelaar I Dorinatal
561	44.	outcomes associated with maternal HIV and antiratroviral therapy in programsian
562		with accurate gestational age in South Africa, AIDS [Internet], 2010 Aug 22(10):1622
562		with accurate gestational age in South Anita. ADS [Internet]. 2019 Aug;33(10):1023-
303		55. Available from: http://insights.ovid.com/crossret?an=00002030-201908010-

564		00010
565	43.	Msukwa MT, Keiser O, Jahn A, van Oosterhout JJ, Edmonds A, Phiri N, et al. Timing of
566		combination antiretroviral therapy (cART) initiation is not associated with stillbirth
567		among HIV-infected pregnant women in Malawi. Trop Med Int Health [Internet].
568		2019 Jun;24(6):727–35. Available from:
569		http://www.ncbi.nlm.nih.gov/pubmed/30891866
570	44.	Onoya D, Sineke T, Brennan AT, Long L, Fox MP. Timing of pregnancy, postpartum risk
571		of virologic failure and loss to follow-up among HIV-positive women. AIDS [Internet].
572		2017;31(11):1593–602. Available from:
573		http://www.ncbi.nlm.nih.gov/pubmed/28463877
574	45.	Dinh T-H, Mushavi A, Shiraishi RW, Tippett Barr B, Balachandra S, Shambira G, et al.
575		Impact of Timing of Antiretroviral Treatment and Birth Weight on Mother-to-Child
576		Human Immunodeficiency Virus Transmission: Findings From an 18-Month
577		Prospective Cohort of a Nationally Representative Sample of Mother–Infant Pairs
578		During the Transition Fro. Clin Infect Dis [Internet]. 2018 Feb 1;66(4):576–85.
579		Available from: https://academic.oup.com/cid/article/66/4/576/4159392
580	46.	Djeha A, Girard S, Trottier H, Kakkar F, Soudeyns H, Boucher M, et al. No association
581		between early antiretroviral therapy during pregnancy and plasma levels of
582		angiogenic factors: a cohort study. BMC Pregnancy Childbirth [Internet]. 2019 Dec
583		9;19(1):482. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31815612
584	47.	Melekhin V V. Shepherd BE. Stinnette SE. Rebeiro PF. Barkanic G. Raffanti SP. et al.
585		Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected
586		women: maternal virologic, immunologic, and clinical response. PLoS One [Internet].
587		2009 Sep 9;4(9):e6961. Available from:
588		http://www.ncbi.nlm.nih.gov/pubmed/19742315
589	48.	Kalk E, Schubert P, Bettinger JA, Cotton MF, Esser M, Slogrove A, et al. Placental
590		pathology in HIV infection at term: a comparison with HIV-uninfected women. Trop
591		Med Int Health [Internet]. 2017;22(5):604–13. Available from:
592		http://www.ncbi.nlm.nih.gov/pubmed/28214384
593	49.	Pillai S, Cheyney M, Everson CL, Bovbjerg ML. Fetal macrosomia in home and birth
594		center births in the United States: Maternal, fetal, and newborn outcomes. Birth
595		[Internet]. 2020 Oct 15;birt.12506. Available from:
596		https://onlinelibrary.wiley.com/doi/10.1111/birt.12506
597	50.	Bouvier D, Forest J-C, Dion-Buteau E, Bernard N, Bujold E, Pereira B, et al. Association
598		of Maternal Weight and Gestational Weight Gain with Maternal and Neonate
599		Outcomes: A Prospective Cohort Study. J Clin Med [Internet]. 2019 Nov
600		27;8(12):2074. Available from: https://www.mdpi.com/2077-0383/8/12/2074
601	51.	Madlala HP, Malaba TR, Newell M, Myer L. Elevated body mass index during
602		pregnancy and gestational weight gain in HIV-infected and HIV-uninfected women in
603		Cape Town, South Africa: association with adverse birth outcomes. Trop Med Int Heal
604		[Internet]. 2020 Jun 23;25(6):702–13. Available from:
605		https://onlinelibrary.wiley.com/doi/10.1111/tmi.13387
606	52.	Fahme SA, Bloomfield GS, Peck R. Hypertension in HIV-Infected Adults. Hypertension
607		[Internet]. 2018 Jul;72(1):44–55. Available from:
608		https://linkinghub.elsevier.com/retrieve/pii/S1473309914708965
609	53.	Kovo M, Bar J, Schreiber L, Shargorodsky M. The relationship between hypertensive
610		disorders in pregnancy and placental maternal and fetal vascular circulation. J Am Soc
611		Hypertens [Internet]. 2017 Nov;11(11):724–9. Available from:
612		https://linkinghub.elsevier.com/retrieve/pii/S1933171117303054
613	54.	Bustamante Helfrich B, Chilukuri N, He H, Cerda SR, Hong X, Wang G, et al. Maternal
614		vascular malperfusion of the placental bed associated with hypertensive disorders in
615		the Boston Birth Cohort. Placenta [Internet]. 2017 Apr;52:106–13. Available from:

616		https://linkinghub.elsevier.com/retrieve/pii/S0143400417301595
617	55.	Naderi S, Tsai SA, Khandelwal A. Hypertensive Disorders of Pregnancy. Curr
618		Atheroscler Rep [Internet]. 2017 Mar 22;19(3):15. Available from:
619		http://link.springer.com/10.1007/s11883-017-0648-z
620	56.	Govender N, Naicker T, Moodley J. Maternal imbalance between pro-angiogenic and
621		anti-angiogenic factors in HIV-infected women with pre-eclampsia. Cardiovasc J Afr
622		[Internet]. 2013 Jun;24(5):174–9. Available from:
623		http://www.ncbi.nlm.nih.gov/pubmed/24217170
624	57.	Graham SM, Rajwans N, Jaoko W, Estambale BBA, McClelland RS, Overbaugh J, et al.
625		Endothelial activation biomarkers increase after HIV-1 acquisition. AIDS [Internet].
626		2013 Jul;27(11):1803–13. Available from:
627		http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002
628		030-201307170-00014
629	58.	Graham SM, Rajwans N, Tapia KA, Jaoko W, Estambale BB, McClelland RS, et al. A
630		prospective study of endothelial activation biomarkers, including plasma
631		angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy.
632		BMC Infect Dis [Internet]. 2013 Dec 4;13(1):263. Available from:
633		https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-13-263
634	59.	Mohammadi H, Papp E, Cahill L, Rennie M, Banko N, Pinnaduwage L, et al. HIV
635		antiretroviral exposure in pregnancy induces detrimental placenta vascular changes
636		that are rescued by progesterone supplementation. Sci Rep [Internet]. 2018 Dec
637		26;8(1):6552. Available from: http://www.nature.com/articles/s41598-018-24680-w
638		
639		

TABLES

641 Table 1: Maternal and obstetric characteristics of the pregnant women at enrolment.

	Total N=130	¹ ART Initiation before pregnancy	ART Initiation during pregnancy	p-Value
		IN-33	IN-77	<0 0001
<74	24 (18 5)	5 (9 4)	19 (24 7)	(0.0001
25-29	36 (27 7)	10 (18 9)	26 (33.8)	
30-34	37 (285)	14 (26 4)	23 (29 9)	
>35	33 (25.4)	24 (45 3)	9 (11 7)	
Median (IOR)	31 (26 - 35)	33(28 - 37)	28 (25 - 32)	
Median Gestation at	15 (11 19)	14 (11 19)	15 (11 10)	0.4
Enrolment	13 (11-18)	14 (11-10)	(11-16)	0.4
Gravidity				0.1
1	14 (10.8)	4 (7.5)	10 (13.0)	
2	50 (38.5)	16 (30.2)	34 (44.2)	
≥3	66 (50.8)	33 (62.3)	33 (42.9)	
Median (IQR)	3 (2-3)	3 (2-4)	2 (2-3)	
² Previous Preterm				1.0
Yes	7 (5.4)	4 (7.5)	3 (3.9)	
ART regimen				0.2
TDF-3TC-EFV	119 (91.5)	47 (88.7)	72 (93.5)	
AZT-3TC-NVP	2 (1.5)	1 (1.9)	1 (1.9)	
AZT-XTC-EFV	6 (4.6)	2 (3.8)	4 (5.2)	
PI-based regimen	3 (2.3)	3 (5.7)	0 (0)	
³ CD4 cell count, cells/ml				0.04
≤ 200	9 (6.9)	1 (1.9)	8 (10.4)	
201-350	32 (24.6)	8 (15.1)	24 (31.2)	
351-500	29 (22.3)	14 (26.4)	15 (19.5)	
>500	41 (31.5)	20 (37.7)	21 (27.3)	
Median (IQR)	416 (311 - 589)	455 (381 - 602)	369.5 (251 - 534.5)	
Missing	19 (14.6)	10 (18.9)	9 (11.7)	
³ Viral load, copies/ml				0.1
<400	84 (64.6)	45 (84.9)	39 (50.6)	
401-1000	2 (1.5)	0 (0)	2 (2.6)	
>1000	7 (5.4)	2 (3.8)	5 (6.5)	
Median (IQR)	20 (20 - 27)	20 (20 - 27)	20 (20 - 34)	
Missing	37 (28.5)	6 (11.3)	31 (40.3)	
⁴ Body Mass Index, kg/m ²				0.5
Normal (18.5-24.9)	27 (20.7)	12 (22.6)	15 (19.5)	
Overweight (25.0-29.9)	41 (31.5)	18 (34.0)	23 (29.9)	
Obese (>30.0)	61(46.9)	22 (41.5)	39 (50.6)	
Median (IQR)	29.45 (25.5 - 33.6)	29.2 (25.8 - 32.2)	30 (25.4 -35.2)	
Missina	1 (0.8)	1 (1.9)	0 (0)	
Blood Pressure, Enrolment				
(mmHG)				0.03
Norma	99 (76 1)	16 (96 9)	52 (69 9)	
(Sys <120 and Dia <80)	99 (70.1)	40 (00.0)	00.00	
Prehypertensive (Sys 120-139 or Dia 80-89)	28 (21.5)	6 (11.3)	22 (28.6)	
Hypertensive (Sys >140 or Dia >90)	3 (2.3)	1 (1.9)	2 (2.6)	

- 643 ¹Differences between the two groups were assessed using a two-sample t-test or Wilcoxon rank-sum test
- 644 depending on the distribution for numerical data and the chi² test or Fisher's exact test for categorical data.
- 645 ²Among women with a previous pregnancy
- 646 ³CD4 and viral load results abstracted from routine records and are the nearest in time to the first ANC visit.
- 647 ⁴At enrolment or first ANC

Table 2: Infant characteristics

	Total N=130 58 (44.6) 72 (55.4)	ART Initiation before pregnancy	ART Initiation during pregnancy	p-
	N=130	N=53	N=77	value
Sex				0.6
Female	58 (44.6)	25 (47.2)	33 (42.9)	
Male	72 (55.4)	28 (52.8)	44 (57.1)	
Median Delivery Gestation	20 (28 10)	20 (28 20)	20 (28 10)	0 1
(completed weeks)	59 (58 - 40)	55 (56 - 55)	39 (38 - 40)	0.1
Birthweight, grams				0.2
Low birthweight (<2500g)	11 (8.5)	6 (11.3)	5 (6.5)	
Normal (2500 - 4000g)	111 (85.4)	46 (86.8)	65 (84.4)	
High (>4000g)	8 (6.1)	1 (1.9)	7 (9.1)	
Median (IQR)	3180 (2880 - 3540)	3140 (2690 - 3360)	3240 (2940 - 3580)	
Preterm (<37 weeks				1.0
Gestational Age)				1.0
Yes	9 (6.9)	4 (7.5)	5 (6.5)	
No	121 (93.1)	49 (92.5)	72 (93.5)	
Size for Gestational Age, <10 th				0.07
centile				0.07
Yes	12 (9.2)	8 (15.1)	4 (5.2)	
No	118 (90.8)	45 (84.9)	73 (94.8)	
Mode of Delivery				0.2
Vaginal Delivery	97 (74.6)	42 (79.2)	55 (71.4)	
Elective Caesarean	24 (18.5)	4 (7.6)	4 (5.2)	
Emergency Caesarean	8 (6.1)	6 (11.3)	18 (23.4)	
Missing	1 (0.8)	1 (1.9)	0 (0)	

 1 Differences between the two groups were assessed using a two-sample t-test or Wilcoxon rank-sum test

652 depending on the distribution for numerical data and the chi² test or Fisher's exact test for categorical data.

654 Table 3: Placental characteristics and pathology at delivery among women initiating ART

655 **before or during pregnancy.**

	Total	¹ ART Initiation	ART Initiation	
	N=130	before pregnancy N=53	during pregnancy N=77	P-value
Placental weight (g), median (IQR)	412 (346 - 480)	392 (346 – 440)	422 (344 – 490)	0.09
Placental weight (g)				1.0
Small (<10 th percentile)	43 (33.1)	17 (32.1)	26 (33.8)	
Appropriate (10 – 90 th	95 (C5 A)	25 (66 0)	50(61 9)	
percentile)	85 (85.4)	55 (0.0)	50 (64.5)	
Large (>90 th percentile)	1 (0.8)	0 (0)	1(1.3)	
Missing	1 (0.8)	1(1.9)	0(0)	
Fetal-Placenta weight ratio				0.9
Small (<10 th percentile)	3 (2.3)	1 (1.9)	2 (2.6)	
Appropriate (10 – 90 th percentile)	81 (62.3)	32 (60.4)	49 (63.6)	
Large (>90 th percentile)	45 (34.6)	19 (35.8)	26 (33.8)	
Missing	1 (0.8)	1(1.9)	0(0)	
Placenta greatest diameter (mm),	470 (460 400)		170 (100 100)	0.1
median (IQR)	170 (160 – 180)	172 (161 – 189)	170 (160 - 180)	0.1
Placenta thickness (mm), median		15/10 22)	20 (10 25)	0.4
(IQR)	17.5 (10 - 25)	15 (10 - 22)	20 (10 - 25)	0.4
Cord insertion				0.1
Central	20 (15.4)	6 (11.3)	14 (18.2)	
Off centre	88 (67.7)	34 (64.1)	54 (70.1)	
Marginal	16 (12.3)	10 (18.9)	6 (7.8)	
Missing	6 (4.6)	3(5.7)	3(3.9)	
Meconium exposure				0.9
+	25 (19.2)	10 (18.9)	15 (19.5)	
-	105 (80.8)	43 (81.1)	62 (80.5)	
Chorioamnionitis				
Maternal Inflammatory Response				0.8
+	19 (14.6)	7 (13.2)	12 (15.6)	
-	111 (85.4)	46 (86.3)	65 (84.4)	
Fetal Inflammatory Response				0.1
+	20 (15.4)	5 (9.4)	15 (19.5)	
-	110 (84.6)	48 (90.6)	62 (80.5)	
Chronic Deciduitis				0.8
+	14 (10.8)	5 (9.4)	9 (11.7)	
-	116 (89.2)	48 (90.6)	68 (88.3)	
Maternal Vascular Malperfusion				0 01
(MVM)				0.01
+	36 (27.7)	21 (39.6)	15 (19.5)	
-	94 (72.3)	32 (60.4)	62 (80.5)	

656 ¹Differences between the two groups were assessed using a two-sample t-test or Wilcoxon rank-sum test

657 depending on the distribution for numerical data and the chi² test or Fisher's exact test for categorical data.

	¹ P	reterm delive	ry	¹ Size for gestational age ¹ Low birth (<10 th centile)		birthweight (<	thweight (<2500g)		
	Y (%)	N (%)	р	Y (%)	N (%)	р	Y (%)	N (%)	р
Percentile placental weight			0.7			0.1			1.0
<10 th	2 (23)	41 (34)		7 (58)	36 (30)		4 (36)	39 (33)	
>10 th	6 (67)	80 (66)		5 (42)	81 (69)		7 (64)	79 (66)	
Missing	1 (11)	0 (0)		0(0)	1(1)		0 (0)	1(1)	
Cord insertion			0.2			1.0			0.1
Central	3 (33)	17 (14)		2 (17)	18 (15)		4 (36)	16 (13)	
Off centre	5 (56)	83 (69)		8 (67)	80 (68)		7 (64)	81 (68)	
Margina	0 (0)	16 (13)		1 (8)	15 (13)		0(0)	16(14)	
Missing	1 (11)	5 (4)		1 (8)	5 (4)		0 (0)	6 (5)	
Meconium exposure			1.0			0.01			0.7
+	1(11)	24 (19)		6 (50)	19 (16)		1 (9)	24 (20)	
<u> </u>	8 (89)	97 (80)		6 (50)	99 (84)		10 (91)	95 (78)	
Chorioamnionitis									
Maternal Inflammatory Response			0.4			0.4			0.4
+	0 (0)	19 (16)		3 (25)	16 (14)		0	19 (16)	
-	9 (100)	102 (84)		9 (75)	102 (86)		11 (100)	100 (84)	
Fetal Inflammatory Response			0.4			1.0			0.2
+	0	20 17)		2 (17)	18 (15)		0	20(17)	
-	9 (100)	101 (83)		10 (83)	100 (85)		11 (100)	99 (83)	
Chronic Deciduitis			1.0			0.4			0.4
+	1(11)	13 (11)		0	14 (12)		2 (18)	12 (10)	
<u>-</u>	8 (89)	108 (89)		12 (100)	104 (88)		9 (82)	107 (90)	
Decidual arteriopathy			0.07			0.5			0.1
+	2 (22)	5 (4)		1 (8)	6 (5)		2 (18)	5 (4)	
-	7 (78)	116 (96)		11 (92)	112 (95)		9 (82)	114 (96)	
Naternal Vascular Malperfusion (MVM)			0.002			0.09			<0.0001
+	7 (78)	29 (24)		6 (50)	30 (25)		10 (91)	26 (22)	
-	2 (23)	92 (76)		6 (50)	88 (75)		1 (9)	93 (78)	

659 Table 4: Relationship between placenta pathology and preterm delivery, size for gestational age and low birthweight.

660

¹To assess potential risk factors for preterm delivery (<37 weeks gestational age), size for gestational age (<10th percentile) and low birth weight (<2500g), we compared

662 differences between groups using the chi² test or Fisher's exact test.

	Total	ART Initiation before	ART Initiation	
	10tai	pregnancy	during pregnancy	p-Value
	N=130	N=53	N=77	
ubstance Use†				
Alcohol				0.2
Yes	22 (16.9)	6 (11.3)	16 (20.8)	
No	105 (80.8)	45 (84.9)	60 (77.9)	
Missing	3 (2.3)	2 (3.8)	1 (1.3)	
Smoking				0.1
Yes	7 (5.4)	5 (9.4)	2 (2.6)	
No	121 (93.1)	46 (86.8)	75 (97.4)	
Missing	2 (1.5)	2 (3.8)	0 (0)	
Drugs				0.5
Yes	2 (1.5)	O (O)	2 (2.6)	
No	126 (96.9)	51 (96.2)	75 (97.4)	
Missing	2 (1.5)	2 (3.8)	0 (0)	

663 Supplementary Table 1: Substance use among study participants.

664 ⁺Substance use is self-reported over the last 30 days

665 ¹Differences between the two groups were assessed using a two-sample t-test or Wilcoxon rank-sum test

666 depending on the distribution for numerical data and the chi² test or Fisher's exact test for categorical data.

668 Supplementary Table 2: Maternal and obstetric characteristics of pregnant women at enrolment: comparing no placenta vs placenta 669 collection.

	Total	No Placenta	Placenta	p-value	No Pla	acenta 421		Plac N=*	enta 120	p-value
					ART Initiation	ART Initiation		N-		
	N=551	N=421	N=130		before pregnancy N=208	during pregnancy N=213	p-value	ART Initiation before pregnancy N=53	ART Initiation during pregnancy N=77	
Age, years				0.6			<0.001			<0.001
≤24	92 (16.7)	68(16.2)	24 (18.5)		20 (9.6)	48 (22.5)		5 (9.4)	19 (24.7)	
25-29	156 (28.3)	120 (28.5)	36 (27.7)		48 (23.1)	72 (33.8)		10 (18.9)	26 (33.8)	
30-34	179 (32.5)	142 (33.7)	37 (28.5)		74 (35.6)	68 (31.9)		14 (26.4)	23 (29.9)	
≥35	124 (22.5)	91(21.6)	33 (25.4)		66 (31.7)	25 (11.7)		24 (45.3)	9 (11.7)	
Median (IQR)	30 (26-34)	30 (26-34)	31(26-35)		32 (28-35)	29 (25-32)		33 (28 - 37)	28 (25 - 32)	
Median Gestation at Enrolment	14 (10-18)	13 (10-17)	14 (11-18)	0.04	13 (9-16)	14 (10-18)	0.02	13 (10-18)	15 (11-18)	0.2
Gravidity				0.14			0.001			0.1
1	89 (16.1)	75 (17.8)	14 (10.8)		50 (23.5)	25 (12.0)		4 (7.5)	10 (13.0)	
2	189 (34.3)	139 (33.0)	50 (38.5)		76 (35.7)	63 (30.3)		16 (30.2)	34 (44.2)	
≥3	273 (49.6)	207 (49.2)	66 (50.8)		87 (40.8)	120 (57.7)		33 (62.3)	33 (42.9)	
ART regimen				0.1			<0.001			0.2
TDF-3TC-EFV	499 (90.6)	380 (90.3)	119 (91.5)		173 (83.2)	207 (97.2)		47 (88.7)	72 (93.5)	
TDF-3TC-NVP	4 (0.7)	4 (0.9)	0 (0)		2 (0.9)	2 (0.9)		0 (0)	0 (0)	
AZT-3TC-NVP	10 (1.8)	8(1.9)	2(1.6)		8 (3.9)	0(0)		1(1.9)	1 (1.9)	
AZT-XTC-EFV	13 (2.4)	7(1.7)	6 (4.6)		5 (2.4)	2 (0.9)		2 (3.8)	4 (5.2)	
Pl-based regimen	25 (4.5)	22 (5.2)	3 (2.3)		20 (9.6)	2 (0.9)		3 (5.7)	0 (0)	
¹ Body Mass Index, kg/m ²				0.4			0.3			0.6
Normal (18.5-24.9)	115 (20.9)	88 (20.9)	27 (20.8)		38 (18.3)	50 (23.5)		12 (22.6)	15 (19.5)	
Overweight (25.0-29.9)	149 (27.0)	108 (25.7)	41 (31.5)		58 (27.9)	50 (23.5)		18 (34.0)	23 (29.9)	
Obese (>30.0)	282 (51.2)	221 (52.5)	61 (46.9)		111 (53.4)	110 (51.6)		22 (41.5)	39 (50.6)	
Missing	5 (0.9)	4 (0.9)	1(0.8)		1 (0.5)	3 (1.41)		1 (1.9)	0(0)	
Blood Pressure, Enrolment (mmHG)				0.4			0.3			0.03
Normal (Sys <120 and Dia <80)	405 (73.5)	306 (72.7)	99 (76.2)		156 (75.0)	150 (70.4)		46 (86.8)	53 (68.8)	
Prehyperten sive (Sys 120-139 or Dia 80-89)	123 (22.3)	95 (22.6)	28 (21.5)		45 (21.6)	50 (23.5)		6 (11.3)	22 (28.6)	
Hypertensive (Sys >140 or Dia >90)	23 (4.2)	20 (4.7)	3 (2.3)		7 (3.4)	13 (6.1)		1 (1.9)	2 (2.6)	

670 ¹At enrolment or first ANC

671 **FIGURE LEGENDS**

Figure 1A: Digital scan of a representative Haematoxylin and Eosin (H&E) stained sectionshowing chorioamnionitis of the membranes (maternal response).

674

Figure 1B: Digital scan of a representative H&E stained section showing a neutrophilic
infiltrate involving the cord vein wall extending into Wharton's jelly of the cord (fetal
response).

678

Figure 1C: Digital scans of representative H&E stained sections of the placenta showing an
infarct. Insert 1 shows a magnified image of the infarct and Insert 2 shows a magnified foam
cell (denoted by the arrow) within the decidual artery demonstrating atherosis.

682

Figure 2A: Forest plot depicting the relative risk with the 95% confidence intervals of HIV
 infected women presenting with a small placenta (<10th percentile for gestational age).

685

Figure 2B: Forest plot depicting the relative risk with the 95% confidence intervals of HIVinfected women presenting histologic chorioamnionitis.

688

Figure 2C: Forest plot depicting the relative risk with the 95% confidence intervals of HIVinfected women presenting with placental maternal vascular malperfusion.

691

692 Figure 2D: Alluvial plot depicting the impact of ART timing on the placental pathology 693 among women initiating treatment before pregnancy (*Initiating*) or during pregnancy 694 (stable). The plot depicts frequencies from a subset of women with abnormal placenta 695 pathology only. These include CA (Chorioamnionitis depicting FIR Fetal Inflammatory 696 Response; MIR, Maternal Inflammatory Response), CD (Chronic Deciduitis), MVM (Maternal Vascular Malperfusion) and Meconium (Meconium Exposure) and the placenta size i.e. <10th 697 percentile for gestational age (small) and $> 10^{th}$ percentile for gestational age (Normal) 698 among women initiating treatment before pregnancy (Initiating) or during pregnancy 699 700 (stable).

Differential impact of antiretroviral therapy initiated before or during pregnancy on placenta pathology in HIV-positive women.

Figures

Figure 1A



Figure 1A: Digital scan of a representative Haematoxylin and Eosin (H&E) stained section showing chorioamnionitis of the membranes (maternal response).

Figure 1B



Figure 1B: Digital scan of a representative H&E stained section showing a neutrophilic infiltrate involving the cord vein wall extending into Wharton's jelly of the cord (fetal response).

Figure 1C



Figure 1C: Digital scans of representative H&E stained sections of the placenta showing an infarct. Insert 1 shows a magnified image of the infarct and Insert 2 shows a magnified foam cell (denoted by the arrow) within the decidual artery demonstrating atherosis.

Figure 2A

Small Placenta size (<10th percentile)



Figure 2A: Forest plot depicting the relative risk with the 95% confidence intervals of HIV infected women presenting with a small placenta (<10th percentile for gestational age).

Chorioamnionitis



Figure 2B: Forest plot depicting the relative risk with the 95% confidence intervals of HIV infected women presenting histologic chorioamnionitis.

Maternal Vascular Malperfusion



Figure 2C: Forest plot depicting the relative risk with the 95% confidence intervals of HIV infected women presenting with placental maternal vascular malperfusion.

Figure 2D



Figure 2D: Alluvial plot depicting the impact of ART timing on the placental pathology clusters among women initiating treatment before pregnancy (*Initiating*) or during pregnancy (*stable*). The plot depicts frequencies from a subset of women with abnormal placenta pathology only. These include CA (Chorioamnionitis depicting FIR Fetal Inflammatory Response; MIR, Maternal Inflammatory Response), CD (Chronic Deciduitis), MVM (Maternal Vascular Malperfusion) and Meconium (Meconium Exposure) and the placenta size i.e. <10th percentile for gestational age (small) and > 10th percentile for gestational age (Normal) among women initiating treatment before pregnancy (*Initiating*) or during pregnancy (*stable*).